Perelman School of Medicine at the University of Pennsylvania

Cardiovascular Institute (CVI)

  • banner image
  • banner image

Welcome to the Penn Cardiovascular Institute (CVI)


Heart and vascular diseases comprise the leading cause of death in the United States and a major health problem worldwide. Despite significant advances in our understanding and treatment of the origins of atherosclerosis and heart attacks, the complex array of diseases that afflict the cardiovascular system continues to grow. New treatments for these diseases have not kept pace. In order to decipher the origins of the complex diseases that afflict the heart and vasculature, multi-disciplinary approaches are necessary to move fundamental discoveries toward first-in-human trials in an efficient manner. To achieve these goals, the Penn Cardiovascular Institute (CVI) was established in 2005 as a collaborative multi-disciplinary group of basic and translational researchers dedicated to scientific discovery and medical breakthroughs in the understanding and treatment of cardiovascular disease. The CVI has grown substantially since 2007 and includes membership across the Perelman School of Medicine.

 

Our Mission

The mission of the Penn CVI is to promote transformational discoveries in cardiovascular biology and medicine to impact cardiovascular health. The specific goals of the CVI are:

  1. Fundamental discovery to elucidate the pathophysiology of diseases of the heart and vasculature.
  2. Translational studies to rapidly move discovery toward new paradigms in patient care including breakthrough therapies, technologies, and diagnostics.
  3. Train the next generation of cardiovascular scientists poised to engage in fundamental and translational research relevant to cardiovascular disease.

 

 


Penn CVI News:

 

Congratulations to Dr. Rajan Jain for Receiving a New Innovator NIH Director's Award!

Rajan Jain, M.D.
Assistant Professor of Medicine
Perelman School of Medicine

"Rajan Jain, MD, an assistant professor of Medicine and Cell and Developmental Biology and member of the Cardiovascular Institute (CVI) and Institute for Regenerative Medicine (IRM), will be provided $2.4 million to advance understanding how cell identity is established and maintained. This generous support will help his group decode the rules that instruct genome organization and cellular identity, ultimately revealing implications for human disease."

~Penn Medicine News


Dr. Kiran Musunuru Testifying in the US Senate:

Dr. Musunuru briefing staff members of the U.S. Senate Committee on Health, Education, Labor and Pensions about genomic medicine and gene editing on September 28, 2018, in Washington, DC, as a representative of the American Society of Human Genetics.

Photo credits: Ann Klinck.